September 24, 2020 10:39 AM EDTUpdated 03:19 PM
Financing

On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

Max Gelman

Senior Editor

As has been the trend in 2020, Taysha Gene Ther­a­pies has be­come the lat­est biotech to make a quick as­cent from a small, pri­vate­ly-fund­ed com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times